Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Knappertz

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Experimental Neurology|November 28, 2022
Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazamRohini R Rana, Karthik Rajasekaran, Volker Knappertz, et al.
Journal of Neurology|December 28, 2014
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysisRobert Zivadinov, Michael Dwyer, Hadas Barkay, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 21, 2017
Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMSFrancesca Bovis, Nicola De Stefano, Joshua R Steinerman, et al.
Neurology|July 10, 2013
Mortality in patients with multiple sclerosisAntonio Scalfari, Volker Knappertz, Gary Cutter, et al.
Acta Neurologica Scandinavica|June 28, 2020
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trialsOrrin Devinsky, Elizabeth A Thiele, Stephen Wright, et al.
Clinical & Experimental Neuroimmunology|July 15, 2017
Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosisTakashi Yamamura, Natalia Ashtamker, David Ladkani, et al.
Stroke|May 23, 2009
Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhageKurt T Kreiter, Stephan A Mayer, George Howard, et al.
Clinical Therapeutics|June 21, 2011
Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapySuellen M Curkendall, Cheng Wang, Barbara H Johnson, et al.
Plos One|December 6, 2011
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSDouglas S Goodin, Jason Jones, David Li, et al.
Multiple Sclerosis and Related Disorders|September 9, 2015
Causes of death among persons with multiple sclerosisGary R Cutter, Jeffrey Zimmerman, Amber R Salter, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Experimental Neurology|November 28, 2022
Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazamRohini R Rana, Karthik Rajasekaran, Volker Knappertz, et al.
Journal of Neurology|December 28, 2014
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysisRobert Zivadinov, Michael Dwyer, Hadas Barkay, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 21, 2017
Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMSFrancesca Bovis, Nicola De Stefano, Joshua R Steinerman, et al.
Neurology|July 10, 2013
Mortality in patients with multiple sclerosisAntonio Scalfari, Volker Knappertz, Gary Cutter, et al.
Acta Neurologica Scandinavica|June 28, 2020
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trialsOrrin Devinsky, Elizabeth A Thiele, Stephen Wright, et al.
Clinical & Experimental Neuroimmunology|July 15, 2017
Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosisTakashi Yamamura, Natalia Ashtamker, David Ladkani, et al.
Stroke|May 23, 2009
Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhageKurt T Kreiter, Stephan A Mayer, George Howard, et al.
Clinical Therapeutics|June 21, 2011
Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapySuellen M Curkendall, Cheng Wang, Barbara H Johnson, et al.
Plos One|December 6, 2011
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSDouglas S Goodin, Jason Jones, David Li, et al.
Multiple Sclerosis and Related Disorders|September 9, 2015
Causes of death among persons with multiple sclerosisGary R Cutter, Jeffrey Zimmerman, Amber R Salter, et al.
Pageof 5